JAC Advance Access originally published online on July 21, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(2):515-523; doi:10.1093/jac/dkh356
JAC vol.54 no.2 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia
1 Zoom International Clinical Research Group, 290 Montigny Street, Saint-Jerome, Quebec J7Z 5T3, Canada 2 Department of Medicine, Winthrop University Hospital, Mineola, NY; 3 State University of New York at Stony Brook, NY; 4 Aventis, Bridgewater, NJ, USA
* Corresponding author. Tel: +1-450-431-8764; Fax: +1-450-431-4175; Email: zoominternational.tellier{at}qc.aira.com
Objectives: This study was conducted to investigate the potential equivalence in clinical efficacy and assess safety of a 5 or 7 day regimen of oral telithromycin (800 mg once daily) and a 10 day regimen of oral clarithromycin (500 mg twice daily) in treating community-acquired pneumonia (CAP). Bacteriological efficacy was also compared.
Methods: This was a multicentre, randomized, double-blind, active-controlled study. Patients with mild to moderate CAP received telithromycin 800 mg once a day for 5 (n=193) or 7 (n=195) days or clarithromycin 500 mg twice a day for 10 days (n=187). In these groups, 159, 161 and 146 patients, respectively, completed the study.
Results: At the post-therapy/test-of-cure evaluation, clinical cure rates (per-protocol clinical population) were 89.3% (5 days) and 88.8% (7 days) for telithromycin, and 91.8% for clarithromycin 10 days. Satisfactory bacteriological outcome rates (per-protocol bacteriological population) were 87.7% and 80.0% for 5 and 7 days of telithromycin, respectively, and 83.3% for 10 days of clarithromycin. Bacteriological eradication rates in the respective treatment groups were, for Streptococcus pneumoniae, 95.8% (23/24), 96.7% (29/30) and 88.5% (23/26); for Haemophilus influenzae, 88.0% (22/25), 84.0% (21/25) and 88.2% (15/17) and for Moraxella catarrhalis, 1/1, 4/5 and 3/4. Both telithromycin regimens demonstrated clinical efficacy against pneumococcal bacteraemia (19/19), atypical pathogens (9/9) and erythromycin-resistant S. pneumoniae isolates (5/5). Most treatment-emergent adverse events were mild to moderate in intensity with most commonly reported adverse events involving the gastrointestinal system.
Conclusions: Telithromycin 800 mg administered once a day for 5 or 7 days was as effective and safe as clarithromycin 500 mg administered twice a day for 10 days in treating patients with CAP caused by common respiratory pathogens, including macrolide-resistant isolates, and pneumococcal bacteraemia.
Keywords: ketolides , macrolides , antimicrobial resistance , pneumococcal pneumonia , bacteraemia , atypical , intracellular pathogens
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Bolesta and B. P. Roslund Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review Am. J. Health Syst. Pharm., January 1, 2008; 65(1): 37 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. File Jr, L. A. Mandell, G. Tillotson, K. Kostov, and O. Georgiev Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study J. Antimicrob. Chemother., July 1, 2007; 60(1): 112 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Martin, S. Quilici, T. File, J. Garau, A. Kureishi, and M. Kubin Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance J. Antimicrob. Chemother., May 1, 2007; 59(5): 977 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Clay, J. S. Hanson, S. D. Pope, R. W. Rissmiller, P. P. Purdum III, and P. M. Banks Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review Ann Intern Med, March 21, 2006; 144(6): 415 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Faccone, P. Andres, M. Galas, M. Tokumoto, A. Rosato, and A. Corso Emergence of a Streptococcus pneumoniae Clinical Isolate Highly Resistant to Telithromycin and Fluoroquinolones J. Clin. Microbiol., November 1, 2005; 43(11): 5800 - 5803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kasbekar and P. S. Acharya Telithromycin: The first ketolide for the treatment of respiratory infections Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Pass, M. M. Gearhart, and E. J. Young Short-Course Antimicrobial Therapy for the Treatment of Pneumonia Journal of Pharmacy Practice, February 1, 2005; 18(1): 18 - 24. [Abstract] [PDF]
|
|